IDEXX Laboratories, Inc. vs CarMax, Inc — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while CarMax, Inc trades at $56.41 (market cap $7.93B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.6× CarMax, Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | KMX | |
|---|---|---|
Market Cap | $44.48B | $7.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $63.53 |
52-Week Low | $520.87 | $30.88 |
Enterprise Value | $45.38B | $26.44B |
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
CarMax (KMX) trades at $55.89, down 2.51% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported mixed earnings, with a Q2 2025 miss but subsequent beats in Q3 2025 and Q1 2026. Revenue has trended down from $31.9B in 2022 to $26.35B in 2025, though net income margin improved slightly to 1.89%. Recent news highlights a strategic turnaround under new CEO Keith Barr, with insider buying and positive analyst updates despite an ongoing legal investigation.
The outlook for KMX hinges on successful execution of its four-pillar strategy to boost volume and efficiency, offering potential upside if targets are met. However, high debt levels, margin pressure, and legal scrutiny pose significant risks. Analyst consensus is cautious with a hold-heavy rating and a price target of $48.91 below the current price, indicating skepticism about near-term growth.
Trailing returns across standard periods
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →